Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists

Anne H. Blaes, G. J. van Londen, Nicole Sandhu, Amir Lerman, Daniel A. Duprez

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of review: The purpose of this review is to summarize the current literature on estrogen and progesterone antagonists and their effects on the cardiovascular system. Recent findings: Estrogen and progesterone antagonists reduce cancer-related recurrence and mortality in women with ER-positive breast cancer. Recent studies, however, suggest that women with early stage breast cancer are more likely to die of cardiovascular disease than recurrent breast cancer. Estrogen antagonists have been shown to reduce endothelial function, to increase lipid profiles and to alter body composition accelerating atherosclerotic changes. Summary: While clinical trial data demonstrates mixed results of the impact of estrogen antagonists on cardiovascular risk, there is a growing body of evidence that estrogen suppression and estrogen antagonists result in biologic effects on the endothelium, altering lipid profiles and accelerating the risk of atherosclerosis. Further longitudinal work however is needed.

Original languageEnglish (US)
Article number48
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume20
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Estrogen Antagonists
Progesterone
Estrogens
Breast Neoplasms
Lipids
Cardiovascular System
Body Composition
Endothelium
Atherosclerosis
Cardiovascular Diseases
Clinical Trials
Recurrence
Mortality
Neoplasms

Keywords

  • Aromatase inhibitors
  • Breast cancer
  • Cardiovascular risk
  • Estrogen antagonists

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists. / Blaes, Anne H.; van Londen, G. J.; Sandhu, Nicole; Lerman, Amir; Duprez, Daniel A.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 20, No. 6, 48, 01.06.2018.

Research output: Contribution to journalReview article

@article{0b9d2e6691d24ba6816da26b2b3f9b5e,
title = "Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists",
abstract = "Purpose of review: The purpose of this review is to summarize the current literature on estrogen and progesterone antagonists and their effects on the cardiovascular system. Recent findings: Estrogen and progesterone antagonists reduce cancer-related recurrence and mortality in women with ER-positive breast cancer. Recent studies, however, suggest that women with early stage breast cancer are more likely to die of cardiovascular disease than recurrent breast cancer. Estrogen antagonists have been shown to reduce endothelial function, to increase lipid profiles and to alter body composition accelerating atherosclerotic changes. Summary: While clinical trial data demonstrates mixed results of the impact of estrogen antagonists on cardiovascular risk, there is a growing body of evidence that estrogen suppression and estrogen antagonists result in biologic effects on the endothelium, altering lipid profiles and accelerating the risk of atherosclerosis. Further longitudinal work however is needed.",
keywords = "Aromatase inhibitors, Breast cancer, Cardiovascular risk, Estrogen antagonists",
author = "Blaes, {Anne H.} and {van Londen}, {G. J.} and Nicole Sandhu and Amir Lerman and Duprez, {Daniel A.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s11936-018-0637-8",
language = "English (US)",
volume = "20",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists

AU - Blaes, Anne H.

AU - van Londen, G. J.

AU - Sandhu, Nicole

AU - Lerman, Amir

AU - Duprez, Daniel A.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Purpose of review: The purpose of this review is to summarize the current literature on estrogen and progesterone antagonists and their effects on the cardiovascular system. Recent findings: Estrogen and progesterone antagonists reduce cancer-related recurrence and mortality in women with ER-positive breast cancer. Recent studies, however, suggest that women with early stage breast cancer are more likely to die of cardiovascular disease than recurrent breast cancer. Estrogen antagonists have been shown to reduce endothelial function, to increase lipid profiles and to alter body composition accelerating atherosclerotic changes. Summary: While clinical trial data demonstrates mixed results of the impact of estrogen antagonists on cardiovascular risk, there is a growing body of evidence that estrogen suppression and estrogen antagonists result in biologic effects on the endothelium, altering lipid profiles and accelerating the risk of atherosclerosis. Further longitudinal work however is needed.

AB - Purpose of review: The purpose of this review is to summarize the current literature on estrogen and progesterone antagonists and their effects on the cardiovascular system. Recent findings: Estrogen and progesterone antagonists reduce cancer-related recurrence and mortality in women with ER-positive breast cancer. Recent studies, however, suggest that women with early stage breast cancer are more likely to die of cardiovascular disease than recurrent breast cancer. Estrogen antagonists have been shown to reduce endothelial function, to increase lipid profiles and to alter body composition accelerating atherosclerotic changes. Summary: While clinical trial data demonstrates mixed results of the impact of estrogen antagonists on cardiovascular risk, there is a growing body of evidence that estrogen suppression and estrogen antagonists result in biologic effects on the endothelium, altering lipid profiles and accelerating the risk of atherosclerosis. Further longitudinal work however is needed.

KW - Aromatase inhibitors

KW - Breast cancer

KW - Cardiovascular risk

KW - Estrogen antagonists

UR - http://www.scopus.com/inward/record.url?scp=85046276238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046276238&partnerID=8YFLogxK

U2 - 10.1007/s11936-018-0637-8

DO - 10.1007/s11936-018-0637-8

M3 - Review article

AN - SCOPUS:85046276238

VL - 20

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 6

M1 - 48

ER -